Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.71.

Several equities analysts recently weighed in on HUMA shares. HC Wainwright assumed coverage on shares of Humacyte in a report on Wednesday. They set a “buy” rating and a $4.00 target price on the stock. Benchmark lowered their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, May 13th.

Humacyte Trading Up 18.5%

Shares of Humacyte stock opened at $2.24 on Friday. The business’s fifty day moving average price is $1.83 and its 200 day moving average price is $3.48. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.97. The stock has a market capitalization of $347.47 million, a P/E ratio of -1.67 and a beta of 1.64.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.46 million. As a group, sell-side analysts predict that Humacyte will post -1.27 EPS for the current year.

Insider Activity

In related news, Director Kathleen Sebelius bought 50,000 shares of the firm’s stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. The trade was a 121.34% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dale A. Sander purchased 20,000 shares of the company’s stock in a transaction dated Thursday, April 10th. The shares were bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Heights Capital Management Inc. acquired a new position in shares of Humacyte during the first quarter valued at $6,863,000. RA Capital Management L.P. acquired a new position in Humacyte during the 1st quarter valued at about $5,648,000. Woodline Partners LP grew its position in Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the last quarter. Monashee Investment Management LLC acquired a new stake in shares of Humacyte in the first quarter valued at approximately $3,410,000. Finally, CenterBook Partners LP acquired a new stake in shares of Humacyte in the fourth quarter valued at approximately $6,463,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.